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Abstract
The HIV-1 auxiliary protein Vpr and Vpr-fusion proteins can be copackaged with Gag precursor (Pr55Gag) into virions or
membrane-enveloped virus-like particles (VLP). Taking advantage of this property, we developed a simple and sensitive
method to evaluate potential inhibitors of HIV-1 assembly in a living cell system. Two proteins were coexpressed in
recombinant baculovirus-infected Sf9 cells, Pr55Gag, which formed the VLP backbone, and luciferase fused to the N-
terminus of Vpr (LucVpr). VLP-encapsidated LucVpr retained the enzymatic activity of free luciferase. The levels of luciferase
activity present in the pelletable fraction recovered from the culture medium correlated with the amounts of extracellular
VLP released by Sf9 cells assayed by conventional immunological methods. Our luciferase-based assay was then applied to
the characterization of betulinic acid (BA) derivatives that differed from the leader compound PA-457 (or DSB) by their
substituant on carbon-28. The beta-alanine-conjugated and lysine-conjugated DSB could not be evaluated for their antiviral
potentials due to their high cytotoxicity, whereas two other compounds with a lesser cytotoxicity, glycine-conjugated and
e-NH-Boc-lysine-conjugated DSB, exerted a dose-dependent negative effect on VLP assembly and budding. A fifth
compound with a low cytotoxicity, EP-39 (ethylene diamine-conjugated DSB), showed a novel type of antiviral effect. EP-39
provoked an aberrant assembly of VLP, resulting in nonenveloped, morula-like particles of 100-nm in diameter. Each morula
was composed of nanoparticle subunits of 20-nm in diameter, which possibly mimicked transient intermediates of the HIV-1
Gag assembly process. Chemical cross-linking in situ suggested that EP-39 favored the formation or/and persistence of
Pr55Gag trimers over other oligomeric species. EP-39 showed a novel type of negative effect on HIV-1 assembly, targeting
the Pr55Gag oligomerisation. The biological effect of EP-39 underlined the critical role of the nature of the side chain at
position 28 of BA derivatives in their anti-HIV-1 activity.
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Introduction
The majority of antivirals against HIV-1 target the following
steps of virus-cell interaction : (i) fusion between virus envelope
and cell plasma membrane, (ii) reverse transcription of the viral
genomic RNA, (iii) provirus integration into the host genome, and
(iv) viral protease (PR)-mediated processing of HIV-1 polyprotein
precursors (reviewed in [1,2]). The accumulation of immature,
noninfectious virus particles due to unprocessed or partially
processed polyprotein precursors could be provoked by anti-PR
inhibitors, or by a novel class of antivirals derived from betulinic
acid [3]. The prototype of this family of antiviral drugs is the 3-O-
(3’,3’-dimethylsuccinyl)-betulinic acid, abbreviated DSB, known as
YK-FH312 [4] or PA-457 [5], and used in the clinics as
BevirimatTM [5-10]. In the nanomolar range, PA-457 interferes
with the PR-mediated proteolytic cleavage of the Pr55Gag
polyprotein substrate at the junction of the capsid (CA) and
nucleocapsid (NC) domains, resulting in particles with higher
CAp25 content (CAp25= CAp24+SP1) and lower infectivity
[5,8,10,11]. In the micromolar range and in a heterologous
system, we showed that PA-457 has a negative effect on the
assembly and egress of virus-like particles (VLP) formed of
Pr55Gag [12]. Further confirmation of the structural effects of
PA-457 was provided in a recent study, showing that PA-457 used
at micromolar concentrations freezes the lattice of protein shell
underlying the HIV-1 envelope in its immature configuration [13].
All these studies clearly indicate that the structural component
Pr55Gag and its assembly process is a true therapeutic target for
anti-HIV drug therapy (reviewed in [14]). An increasing number
of inhibitors of Gag assembly are being identified and character-
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ized, e.g. viral core- or cytoskeleton-destabilizing agents (reviewed
in [15]), chemicals directed towards the MA, CA or NC domains
[16,17], or Gag-interacting peptides competing with domains of
Gag-Gag interaction [18,19]. As a corollary, there is a need to
develop sensitive and reliable bioassays for virus assembly
inhibitors, based on simple, easy and low cost experimental
approaches mimicking the in vivo situation. HIV-1 Gag precursor
contains all the morphopoietic information required for the
assembly of virus particles, and expression of Pr55Gag in various
heterologous cellular [20–22], or acellular contexts [23] has
proven to be a very convenient method to dissect the natural
process which occurs in HIV-1-infected cells. Furthermore,
membrane-enveloped HIV-1 VLP produced by recombinant
baculovirus-infected insect cells are structurally indistinguishable
from immature particles isolated from HIV-1-infected human cells
[24], and their high productivity permits valuable statistical
analyses of altered morphological and immunological features of
Gag mutant particles [24–33].
The assay for HIV-1 Gag assembly that we developed in the
present study is based on the observation that Vpr and Gag
precursor are coencapsidated into immature particles of HIV-1
[34,35], and on the evidence that Vpr is a bona fide structural
component of the viral core [36–39]. Vpr is copackaged with Gag
through the interaction of the N-terminal alpha-helical domain of
Vpr encompassing residues 17–33 [40–43] with the LXXLFG
motif in the p6 domain of Gag [37,38,44–48]. Taking advantage
of this unique property, we fused the luciferase gene from Photinus
pyralis firefly luciferase to the vpr gene of HIV-1, and expressed the
luciferase-Vpr fusion protein (LucVpr) in Sf9 cells, using a
recombinant baculovirus. When LucVpr was co-expressed with
HIV-1 Pr55Gag, luciferase activity was recovered in the
extracellular VLP fractions, as a result of the Vpr-mediated
encapsidation of the enzyme. The stoichiometry of LucVpr-to-
Pr55Gag polyprotein was not significantly different from the Vpr-
to-Pr55Gag ratio in HIV-1 virions.
Assembly and egress of VLP could therefore be quantitatively
determined in Sf9 cell culture medium using a luciferase-Vpr
packaging-based assay, and we used this assay to evaluate and
compare the efficacy of a panel of derivatives of betulinic acid (BA)
as potential HIV-1 assembly inhibitors. This included the well-
documented leader compound PA-457, and five DSB-derived
compounds, glycine-conjugated DSB (ST-327), beta-alanine-
conjugated DSB (EP-48), free e-NH2 or e-N-blocked lysine-
conjugated DSB (EP-62 and EP-47, respectively), and ethylene
diamine-conjugated DSB (EP-39). We distinguished three types of
negative effect on VLP assembly: (i) a progressive, dose-dependent
inhibition of the budding and extracellular release of membrane-
enveloped VLP at the plasma membrane of Pr55Gag-expressing
cells, with no detectable morphological alterations of the VLP
compared to control samples, as described in our previous study
[12]. This pattern was shown by PA-457, EP-47 and ST-327
(group I compounds). (ii) Group II compounds was exemplified by
EP-48 and EP-62, of which the inhibitory effect on VLP
production was not specific, as it paralleled a high cytotoxic
effect. (iii) In the case of EP-39 (group III), we observed aberrant
assembly of Gag polyproteins in the cytoplasm, and their
extracellular release as nonenveloped, morula-like Gag particles.
The EP-39 activity differed therefore from the antiviral effects
previously described for other BA derivatives, e.g. the blockage of
membrane fusion and entry [49,50], the inhibition of maturation
cleavage CAp25-CAp24 [14], and the inhibition of VLP assembly
and budding [12]. The importance of the nature of the side chain
at position 28 in the anti-HIV-1 activity of BA derivatives, as
evidenced by our experimental data, had important implications
in the design of future antivirals belonging to the BA family.
Ultrastructural analyses of the atypical Gag particles produced in
the presence of EP-39 might also provide indirect clues for a better
understanding of the molecular mechanism of the Gag assembly
pathway, and the identification of possible Gag assembly
intermediate steps.
Results
Packaging of Vpr and Vpr-tagged luciferase (LucVpr)
proteins into HIV-1 VLP produced in insect cells
Vpr has been found to be coencapsidated with the HIV-1 Gag
precursor (Pr55Gag) in roughly equimolar ratio to Pr55Gag
[45,46,51,52], a stoichiometry which was later re-evaluated to a
lower ratio of 1 copy of Vpr per 7 Gag molecules [39]. Sf9 cells
were coinfected with two recombinant baculoviruses at equal
multiplicity (MOI 10 each), one expressing HIV-1 Pr55Gag and
the other Vpr or the fusion protein LucVpr. VLP recovered from
the cell culture medium at 48 h pi were analyzed by SDS-PAGE
and Western blotting using anti-Gag and anti-His tag antibodies.
As shown by immunoblot analysis and autoradiogram of VLP
proteins, both Vpr and LucVpr proteins were efficiently packaged
into VLP (Fig. 1). We also observed a luciferase enzymatic activity
associated with extracellular VLP recovered from cells coexpres-
sing Pr55Gag and LucVpr, as detailed below. This suggested that
(i) the LucVpr fusion protein was competent for packaging into
VLP, and (ii) that the luciferase moiety of LucVpr retained its
enzymatic activity after fusion with Vpr. Since some luciferase
enzyme could be carried over during VLP purification, the next
set of experiments were designed to discriminate between VLP-
adsorbed and VLP-incorporated material.
Specificity of LucVpr encapsidation into VLP : Gag-p6
domain-dependence
To determine whether the luciferase activity that was found
associated with HIV-1 VLP represented encapsidated LucVpr,
and not enzyme contaminants adsorbed onto VLP, we coinfected
Sf9 cells with AcMNPV-LucVpr and AcMNPV-GagDp6, a
recombinant baculovirus which expressed a p6-deleted version
of HIV-1 Gag precursor [25,32,33]. In previous studies, we have
shown that the p6 domain is dispensable for VLP budding and
egress from recombinant baculovirus-infected insect cells
[12,32,33,53], and, interestingly, that VLP constituted of p6-
deleted Gag precursor molecules (GagDp6 of 47 kDa) showed a
more regular shape and higher sphericity than VLP constituted of
WT Pr55Gag [28]. Sf9 cells coinfected with AcMNPV-LucVpr
and AcMNPV-Pr55Gag (full-length, wild-type Gag precursor)
served as positive control, and for negative control for VLP
production, Sf9 cells were infected with AcMNPV-LucVpr alone.
Cell culture medium of Sf9 cells coexpressing LucVpr and
Pr55Gag or GagDp6 was collected at 48 h pi, using ultracentri-
fugation through a sucrose cushion followed by a second step of
ultracentrifugation in isopycnic gradient [12,53,54]. The gradient
fractions were analyzed for Gag polyprotein content (Fig. 2 a) and
processed for luciferase assay (Fig. 2 b). Samples from cells
coexpressing Pr55Gag+LucVpr showed a peak of luciferase
activity which coincided with the apparent density of VLP in
sucrose-D2O density, viz. 1.15–1.25 [12,53]. In contrast to these
control samples, no significant luciferase activity was detected in
the VLP-containing fractions from the culture medium of
GagDp6+LucVpr-coexpressing cells : the level of luciferase activity
observed was comparable to the background level found in culture
medium of cells infected with AcMNPV-LucVpr alone (Fig. 2 b).
This result suggested that the luciferase activity that we found
Luciferase Assay for HIV-1 Assembly Inhibitors
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associated with membrane-enveloped HIV-1 VLP was packaging-
specific, and resulted from a p6-dependent packaging process
mediated by the Vpr moiety of the LucVpr fusion protein.
Quantification of VLP assembly based on luciferase assay,
as applied to the prototype assembly inhibitor PA-457
In a previous study we have shown that PA-457 has an
inhibitory effect on the assemby and budding of HIV-1 VLP from
insect cells expressing the recombinant polyprotein Pr55Gag, with
an IC50 of 5–6 mg/ml (corresponding to 8–10 mM). We later
showed that the sensitivity of VLP assembly to the PA-457
inhibitor did not change in the presence of recombinant Vpr
protein coexpressed in Sf9 cells : virus assembly, measured by the
level of extracellular VLP, was inhibited at the same dose of PA-
457, and with the same IC50 value, with or without Vpr [12].
More importantly, we observed that both Pr55Gag and Vpr
protein contents of VLP decreased in parallel with the increasing
doses of PA-457, suggesting that the level of Vpr encapsidation
into VLP reflected well the degree of assembly inhibition [54].
However, it was essential to determine with better accuracy the
degree of correlation between the quantities of Pr55Gag and
LucVpr proteins coencapsidated into membrane-enveloped,
extracellular VLP in the presence of the prototype assembly
inhibitor PA-457.
Sf9 cells were coinfected with AcMNPV-Pr55Gag and
AcMNPV-LucVpr (at a MOI of 10 each), and PA-457 added to
the cell culture at 24 h pi at increasing doses, ranging from 0 to
10 mg/ml, and maintained for 24 h. Cell culture medium was then
harvested at 48 h pi, subjected to the 2-step ultracentrifugation
analysis, and each gradient fraction probed for Gag polyprotein
and luciferase activity, as above. We observed that the peak of
VLP-associated luciferase activity progressively decreased in a PA-
457 dose-dependent manner (Fig. 3 a). The gradient fractions
corresponding to the peak of luciferase activity were pooled, and
the VLP contained in these fractions were pelleted, lysed and
assayed for luciferase content. The luciferase activity was
determined in parallel in the corresponding cell lysates, and the
values of the ratio of VLP-associated to intracellular luciferase
activity were plotted versus the PA-457 concentrations. The curve
confirmed the dose-dependent decrease of VLP-associated lucif-
erase in the presence of PA-457 (Fig. 3 b). It correlated with the
progressive diminution of the levels of extracellular VLP, as shown
by the Pr55Gag signal in Western blot analysis (Fig. 3 b inset,
top). The intracellular expression of Pr55Gag remained virtually
unchanged within this range of PA-457 concentrations (Fig. 3 b
inset, bottom), as already observed [12].
These data suggested that a luciferase assay based on the VLP-
packaging of LucVpr fusion protein could legitimately be used to
quantitate the VLP production and evaluate the efficacy of
antivirals acting at the stage of virus particle assembly and
extracellular budding. As exemplified by this particular experi-
ment, the 50% inhibition VLP formation was observed at a PA-
Figure 1. Packaging of Vpr and LucVpr into HIV-1 VLP produced in Sf9 cells. Sf9 cells were infected with (-) AcMNPV-Pr55Gag alone, or (+)
coinfected with AcMNPV-Pr55Gag and another recombinant baculovirus expressing (a) Vpr or (b, c )Luciferase-Vpr fusion protein (LucVpr). Both Vpr
and LucVpr were tagged with the His6 epitope. VLP were isolated from the culture medium at 48 h pi, using ultracentrifugation in sucrose-D20
density gradient, and each gradient fraction analysed by SDS-PAGE and standard immunoblotting. (a), Western blot reacted with anti-Gag polyclonal
antibody and peroxidase-labeled anti-rabbit IgG antibody, followed by monoclonal anti-His6 tag and phosphatase-labeled anti-mouse IgG antibody.
Pr55Gag polyprotein is revealed in brown, Vpr protein (14 kDa) in blue (lanes 1, 2). (b), Western blot reacted with anti-Gag polyclonal antibody and
phosphatase-labeled anti-rabbit IgG antibody, followed by monoclonal anti-His6 tag and peroxidase-labeled anti-mouse IgG antibody. Pr55Gag
polyprotein is in blue, LucVpr protein (72 kDa) is in brown (lanes 3, 4). (c), Autoradiogram of dried SDS-gel of 35S-labeled VLP released from control
AcMNPV-Pr55Gag-infected cell cultures (lane 5), or from AcMNPV-Pr55Gag+AcMNPV-LucVpr-coinfected cell cultures, both labeled with 35S-
methionine and 35S-cysteine. Lane m, PageRulerTM pretained protein ladder (Fermentas Inc.). Lane m’, Dual ColorTM molecular markers (BioRad).
Molecular masses are indicated in kiloDaltons (kDa). (*), Asterisk indicates the position of the mono-ubiquitinated Gag polyprotein of 62 kDa,
detected by its positive reaction with anti-ubiquitin antibody (not shown).
doi:10.1371/journal.pone.0027234.g001
Luciferase Assay for HIV-1 Assembly Inhibitors
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457 concentration of 2.2–2.5 mg/ml (Fig. 3 b), corresponding to
an IC50 of 3.8–4.2 mM. This value was consistent with the IC50
value of 8–10 mM previously determined using an immuno-
radiochemical assay of VLP [12], a method which could not
compare with the luciferase assay, in terms of sensitivity and
linearity of the response over a wide range of enzyme
concentrations.
However, in the experiments presented in Fig. 3, the possibility
that PA-457 (or any member of this class of inhibitors) might
negatively interfere with cellular functions indirectly involved in
the copackaging of LucVpr and Pr55Gag was envisaged. To
address this issue, we labeled baculovirus infected cell cultures with
35S-methionine and 35S-cysteine, purified the 35S-labeled VLP by
ultracentrifugation, and analyzed their protein content using SDS-
PAGE, and autoradiography and Western blotting (Fig. 4 a, b).
Gag and Vpr protein bands were excised from the gel and their
respective radioactivity content determined by scintillation count-
ing (Fig. 4 c). Of note, Gag was evaluated as the whole Gag
content, including all Gag protein species in our calculation, i.e.
Pr55Gag, Pr41Gag, CAp24, and MAp17, and corrected for the
respective content of sulfur-containing amino acid residues in the
different protein species. We found an average molecular ratio of
5.6060.68 copies of Gag per Vpr molecule (m 6 SD; n= 8) in
VLP produced by Sf9 cells, a value which was close to the value of
7:1 reported for HIV-1 virions released by human cells [36–39].
The same protocol was applied to VLP isolated from PA-457-
treated Sf9 cells coexpressing LucVpr and Pr55Gag. When plotted
versus the PA-457 doses, the Gag-to-LucVpr ratios remained
virtually constant, regardless of the PA-457 dose (Fig. 4 c), with an
average value of 4.9260.25 copies of Gag per LucVpr molecule
(m 6 SD; n= 8). The absence of significant decrease of the
LucVpr:Gag ratio in the presence of increasing doses of PA-457
therefore excluded a possible direct interference of PA-457 with
the LucVpr encapsidation machinery, which could result in
apparent lower values of luciferase activity at high PA-457
concentrations.
The minor difference in the mean values of Vpr:Gag and
LucVpr:Gag ratios (5.6060.68 versus 4.9260.25) was not
significant at the P=0.05 level, and suggested that the fusion of
luciferase to the N-terminus of Vpr did not significantly alter the
encapsidation efficiency of the LucVpr fusion protein, compared
to nonfused Vpr. If one considered an average value of 1 copy of
Vpr or LucVpr per 5 Gag molecules (ca. 20%) the packaging of
Vpr and LucVpr into VLP produced in Sf9 cells was as efficient as
Figure 2. Gag-p6 domain-dependence of LucVpr packaging. Isopycnic ultracentrifugation analysis in sucrose-D20 density gradient of
extracellular VLP isolated from Sf9 cell culture medium. (a), Western blot of the gradient fractions analyzed by SDS-PAGE. Blot was reacted with anti-
Gag polyclonal antibody and phosphatase-labeled anti-rabbit IgG antibody. Lane m, prestained molecular mass markers (PageRulerTM; Fermentas
Inc.). The position of VLP (fractions 10–13; 1.12–1.15 in density) is indicated at the top of the panel. (b), Luciferase activity was assayed on each
gradient fraction, and expressed as relative light units (RLU). Open symbol, Sf9 cells expressing LucVpr alone; filled symbols, Sf9 cells coexpressing
LucVpr and full-length Pr55Gag or p6-deleted Gag (GagDp6). Each gradient fraction was assayed for luciferase activity. Density values are indicated
on the right scale.
doi:10.1371/journal.pone.0027234.g002
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the packaging of Vpr into HIV-1 virions (15% Vpr; [39]). This
important point validated our method of VLP quantification using
Vpr-based luciferase assay and recombinant HIV-1 Gag precursor
in the baculovirus-insect cell expression system.
Evaluation of potential HIV-1 assembly inhibitors using
LucVpr packaging-based assay
We next evaluated four potential HIV-1 Gag assembly
inhibitors derived from PA-457 for their their effect on VLP
production. These compounds differed from the leader compound
by their substituants on carbon-28 (Fig. 5), and might follow a
different cellular uptake pathway, and/or distribute differently in
the cell compartments, compared to PA-457. These compounds
were a glycine-conjugated DSB (ST-327), a beta-alanine-conju-
gated DSB (EP-48), an e-NH-Boc-lysine-conjugated DSB (EP-47),
a lysine-conjugated DSB (EP-62), and an ethylene diamine-
conjugated DSB (EP-39). We compared their effects with those of
PA-457 and of the nonsubstituted product, the betulinic acid (BA).
BA, PA-457, ST-327, EP-47 and EP-39 were administered to Sf9
cells coinfected with AcMNPV-Pr55Gag and AcMNPV-LucVpr
Figure 3. Quantification of VLP assembly and egress using luciferase assay. (a), Ultracentrifugation analysis of VLP. Cells coexpressing
Pr55Gag and LucVpr were untreated (control 0) or treated with PA-457 in DMSO for 24 h at 24 h pi, at increasing concentrations as indicated. VLP
were isolated from the culture medium at 48 h pi by isopycnic ultracentrifugation in sucrose-D20 density gradient, and assayed for luciferase activity,
expressed as relative light units (RLU). (b), Dose-response curve of PA-457 inhibitory effect on VLP production. The ratio of VLP-associated to
intracellular luciferase activity was plotted versus PA-457 concentrations. The IC50 value obtained was 2.2–2.4 mg/ml. Inset : VLP production (top) and
intracellular expression of Pr55Gag (bottom) were evaluated in parallel by Western blot analysis using anti-Gag rabbit antibody and phosphatase-
labeled conjugate.
doi:10.1371/journal.pone.0027234.g003
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at 24 h pi, and at increasing concentrations. Drug treatment was
maintained for a further 24 h, and VLP released in the cell culture
medium were pelleted through a sucrose cushion [12]. The
amounts of extracellular VLP recovered in the 48 h-pellets
obtained in the presence of the different inhibitors were
determined using the luciferase assays. After normalization to
the luciferase activity determined in the corresponding cell lysates,
the values of the ratio of VLP-incorporated to cell-associated
luciferase activity were plotted versus the drug concentrations.
Two compounds, EP-48 and EP-62, were found to have a
pronounced cytotoxic effect, and no specific effect on VLP assembly
(Table 1). However, ST-327 and EP-47, as well as the leader
Figure 4. Efficiency of packaging of LucVpr into VLP. (a), Autoradiogram of 35S-labeled VLP. VLP were isolated from the culture medium of
Sf9 cells coinfected with AcMNPV-Pr55Gag and AcMNPV-Vpr (leftmost half of the panel), or AcMNPV-Pr55Gag and AcMNPV-LucVpr (rightmost half of
the panel). After purification by ultracentrifugation in sucrose-D20 density gradient, VLP were analyzed by SDS-PAGE, and autoradiography of the
dried gel. The position of Pr55Gag and its major cleavage products Pr41Gag, CAp24 and MAp17 are indicated, as well as Vpr, LucVpr and the
monobiquitinated form of Pr55Gag (Ub-Gag). (b) Western blot analysis. VLP were analyzed by SDS-PAGE as above, followed by Western blot using
anti-Histidine tag antibody and phosphatase-labeled conjugate. Only the portion of the blot showing the Vpr protein of 14 kDa is presented. (c)
Graphic representation of the Gag:LucVpr ratios as a function of the inhibitor concentrations. Quantification of the VLP content of Pr55Gag,
Pr41Gag, CAp24, MAp17, and LucVpr proteins was performed by excision of their corresponding 35S-labeled band from SDS-gel as shown in (a), and
counting radioactivity in scintillation spectrometer. After correction for the respective number of methionine and cysteine residues in proteins, the
values of the Gag:LucVpr ratio were plotted versus the PA-457 concentrations.
doi:10.1371/journal.pone.0027234.g004
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compound PA-457, showed a net inhibitory effect on VLP assembly
with some differences in their respective efficacy. EP-47 presented
the highest inhibitory activity, with IC50 ranging between 1 and
2 mg/ml, with a mean value at 1.9 mM, versus 5.1 mM for PA-457
and 5.9 mM for ST-327 (Fig. 6 and Table 1). The selectivity index
(SI) values were in the same order of magnitude for EP-47 and PA-
457, but 3-fold lower than PA-457 for ST-327 (Table 1).
Intriguingly, the dose-response curve of VLP assembly inhibi-
tion obtained with EP-39 showed a gentle slope until 8 mg/ml,
followed by a plateau at 60-50% VLP production at concentra-
tions higher than 10 mg/ml (corresponding to a molarity of
15.6 mM; Fig. 6 and Table 1). In addition, EP-39 showed the
lowest level of cytotoxicity, compared to the other drugs including
BA (Table 1). The plateau observed in the inhibition curve of EP-
39 implied the occurrence of a residual production of luciferase-
positive VLP in the presence of high doses of EP-39. This result
was somehow unexpected, since EP-39 inhibited the maturation
cleavage of CAp24-SP1 and decreased the virus infectivity with a
mean IC50 of 16 nM and a SI over 2,000 [55], i.e. a significantly
higher efficiency compared to that of the leader compound PA-
457. Further analysis of the EP-39 biological effects was then
performed to exclude possible faulse negative results.
Biophysical properties of luciferase-positive particles
produced by EP-39-treated cells
The extracellular VLP recovered in the 48 h-pellet of culture
medium of EP-39-treated cells were analyzed by isopycnic
ultracentrifugation in sucrose-D20 density gradient [12,53,54], as
in the experiments of Fig. 2 and 3. Control VLP released by
untreated cells equilibrated at an apparent density of 1.15 (Fig. 7),
consistent with that of membrane-enveloped retroviral particles
[24]. However, residual VLP produced in the presence of EP-39
showed a broader peak of luciferase activity which corresponded
to an average density of 1.17 (Fig. 7). This suggested an
heterogeneity and a change in the composition of the EP-39
VLP compared to control VLP, with a difference in the ratio of
protein to lipids consisting of a higher proportion of proteins versus
lipids in EP-39 VLP. Our next experiments were aimed at
elucidating this point using another approach, based on a
structural analysis.
Structural analysis of EP-39-particles
In a previous study, we have shown that PA-457 added to cell
cultures in the micromolar range had a drastic effect on virus
assembly. At 10 mg/ml (17 mM), PA-457 totally abolished VLP
Figure 5. Structure of betulinic acid derivatives. Note that only carbon-3 and carbon-28 are numbered on the PA-457 formula. Compounds ST-
327, EP-48, EP-39, EP-47 and EP-62 are schematically represented by their only difference with the leader compound PA-457, i.e. the substituant
which amidifies the acidic function carried by carbon-28.
doi:10.1371/journal.pone.0027234.g005
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budding and egress from AcMNPV-Gag-infected Sf9 cells [12]. It
also completely blocked the cytoplasmic assembly of core-like
particles formed of non-N-myristoylated Gag precursor [12]. By
contrast, control, untreated AcMNPV-Gag-infected Sf9 cells were
decorated with VLP budding in abundance from the plasma
membrane (Fig. 8, a; and also refer to [12,28,30,32,33,53]). To
further investigate the molecular and cellular basis for the
difference in the inhibitory effect between the three inhibitors
PA-457, ST-327 and EP-47 on one hand, and EP-39 on the other
hand, we examined by electron microscopy (EM) AcMNPV-Gag-
infected Sf9 cells treated with the different drugs at 5 and 10 mg/
ml for 24 h at 24 h pi. The electron microscopy (EM) pattern
shown by ST-327- and EP-47-treated cells was similar to that of
cells treated with PA-457 at the same concentrations (not shown;
refer to [12]): a net inhibitory effect on VLP assembly and budding
was observed with ST-327- and EP-47.
By contrast to Pr55Gag-expressing Sf9 cells treated with PA-
457, ST-327 or EP-47, or to control, untreated cells showing
membrane-enveloped VLP in the process of budding out (Fig. 8
a), a different type of cellular response to EP-39 was observed.
Electron-dense particles of ca. 100 nm in diameter were observed
within the cytoplasm, (i) isolated or grouped as small clusters
surrounded by a membrane (Fig. 8 b), or (ii) accumulated in
numbers in large cytoplasmic inclusions (Fig. 8 c); (iii)
occasionally, 100 nm-particles were seen in the process of
egressing into the extracellular milieu, directly or indirectly via
vesicles opening to the milieu (Fig. 9). These different types of EM
patterns often coexisted in the same cells.
The 100-nm particles assembled in EP-39-treated cells differed
structurally from the nonenveloped, intracytoplasmic core-like
particles of 100–130 nm in diameter assembled by non-N-
myristoylated Pr55Gag [12,28,30,32,33,53], and from the extra-
cellular, membrane-enveloped VLP released by N-myristoylated
Pr55Gag-expressing cells (Fig. 10, compare panels a and b). At
high magnification, substructures were discernible, conferring to
EP-39-induced 100-nm particles the aspect of morulae (Fig. 10,
c). Morula-like particles had a diameter ranging from 87 to
120 nm (mean diameter, m 6 SD=109.169.2, SD, n=14). Each
morula appeared to be constituted of bead-shaped subunits (or
nanoparticles) ranging from 14 to 27 nm in diameter (m 6
SD=19.463.2; n=17). Many morula-like particles were found to
be irregular in shape, and/or in the process of dismantling and
releasing isolated nanoparticles (Fig. 10 c, d).
Immunoelectron microscopy (IEM) of EP-39-treated cells
showed colloidal gold grain-tagged anti-Gag antibody localized
at the plasma membrane (Fig. 11 a), the cellular compartment
where N-myristoylated Gag polyproteins were addressed. The
immunogold anti-Gag labeling was found to be associated with
protrusions of the plasma membrane with irregular shapes (Fig. 11
Figure 6. Evaluation of the inhibitory activity of BA, PA-457, ST-327, EP-47 and EP39 on VLP assembly, using luciferase-Vpr
packaging-based assay. Aliquots of Sf9 cells coinfected with AcMNPV-Pr55Gag and AcMNPV-LucVpr at equal MOI were treated at 24 h pi with
increasing doses of each inhibitor for 24 h. Cells and culture medium were harvested at 48 h pi, and VLP isolated from the culture medium. Cell
pellets and VLP were then processed for luciferase assay, and the values of the ratio of VLP-incorporated to cell-associated luciferase activity, in
percentage of the control (0 inhibitor), were plotted versus the PA-457 concentrations. In control samples, the fraction of VLP-incorporated luciferase
was usually 5 to 7% of the total activity recovered. E.g., in the experiment illustrated here, the activity recovered was 35.56106 RLU in cell pellets,
versus 2.56106 in extracellular VLP. Note that the inhibition curve of EP-62, which resembled that of ST-327, was not represented for reason of clarity.
doi:10.1371/journal.pone.0027234.g006
Table 1. Efficiency of inhibition of HIV-1 VLP assembly by
betulinic acid derivatives (a).
Compound IC50 (mg/ml) IC50 (mM) CC50 (mM) SI
(b)
BA 18.063.0 39.4 43.8 1.1
PA-457 3.061.0 5.1 93.5 18.7
ST-327 3.861.6 5.9 31.1 5.3
EP-47 1.660.5 1.9 24.7 13.0
EP-62 3.460.4 4.8 3.5 0.7
EP-48 ND (c) ND (c) 4.2 ND (c)
EP-39 NA (d) NA (d) 120.0 ND (c)
(a)The mean values (m) for the 50% inhibitory activity (IC50) on VLP assembly
were given as mg/ml (mean, m 6 SEM ; n = 4), or as mM (m). The mean values
for cytoxicity (CC50) were only given as mM.
(b)The selectivity index (SI) was given by the ratio CC50:IC50.
(c)ND, not determined.
(d)NA, not applicable.
doi:10.1371/journal.pone.0027234.t001
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a-c), suggesting an abortive or aberrant Gag budding. Intracyto-
plasmic 20-nm nanoparticles were also labeled with immunogold
grains (Fig. 11 b, c). Interestingly, 20-nm nanoparticles were
observed in close vicinity of, or even within aberrant VLP (Fig. 11
b, c), a pattern which suggested a continuum of structural
elements between nanoparticles and the aberrant larger particles
assembled in the presence of EP-39.
Chemical cross-linking of Pr55Gag in EP-39-treated and
untreated cells
To further analyse the mechanism of the effect of EP-39 on Gag
polyprotein assembly, untreated and EP-39-treated (10 mg/ml),
Pr55Gag-expressing Sf9 cells were incubated with increasing
concentrations of the chemical cross-linker BS3 at 48 h pi for
30 min at room temperature, then lysed in hypotonic medium in
the presence of BS3 used in the same range of concentrations. The
oligomeric status of the Gag proteins was assessed by SDS-PAGE
and Western blot analysis, using anti-Gag antibody, peroxidase-
labeled complementary antibody and enhanced chemilumines-
cence (ECL). In control, non-cross-linked samples, the proportion
of Pr41Gag (the major spontaneous cleavage product of Pr55Gag)
was higher in EP-39-treated cells compared to untreated cells
(Fig. 12 a). This suggested that EP-39 modified the conformation
of Pr55Gag and made it more sensitive to cellular proteases. In
cross-linked samples without EP-39 treatment, the band of
Pr55Gag monomers decreased rapidly at BS3 concentrations
higher than 10 mM BS3, and in a dose-dependent manner
(Fig. 12 b, leftmost half of the blot, lanes 10, 25, 50). The decrease
was less pronounced in EP-39-treated samples (Fig. 12 b,
rightmost half of the blot, lanes 10 to 50).
Differences in the pattern of Pr55Gag oligomers between
untreated and EP-39-treated cells were also observed, as evidenced
on overexposures and enlargements of the luminograms of
Western blots (Fig. 12 b, c). A discrete band of anti-Gag reacting
protein migrating with an apparent molecular mass of 140–
150 kDa and compatible with the status of Gag trimers, was
detected at between 2 and 10 mM BS3 in control samples. This
band disappeared at higher BS3 concentrations, while, in parallel,
Figure 8. Electron microscopy of Pr55Gag-expressing cells.
Samples of Sf9 cells coinfected with AcMNPV-Pr55Gag and AcMNPV-
LucVpr at equal MOI, were (a) untreated, or (b, c) treated at 24 h pi with
10 mg/ml of EP-39 inhibitor for 24 h, harvested at 48 h pi, and
processed for observation under the electron microscope.
doi:10.1371/journal.pone.0027234.g008
Figure 7. Effect of EP-39 on sedimentation properties of VLP.
Cells coexpressing Pr55Gag and LucVpr were untreated (control) or
treated with EP-39 (10 mg/ml in DMSO) for 24 h at 24 h pi. VLP were
recovered from the culture medium at 48 h pi by ultracentrifugation
through a sucrose cushion, and the VLP pellet further analyzed by
isopycnic ultracentrifugation in sucrose-D20 density gradient. Gradient
fractions were assayed for luciferase activity, expressed as relative light
units (RLU). Open symbols, control VLP ; solid symbols, VLP produced in
the presence of EP-39.
doi:10.1371/journal.pone.0027234.g007
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anti-Gag reacting material of high molecular mass became visible
as a smear within the spacer gel or the loading wells (Fig. 12 b
and c, leftmost half of the blot, lanes 10 and 25). In EP-39-treated
samples however, the band of putative Gag trimers progressively
was maximum at 25 mM BS3, and still detectable up to 50 mM
(Fig. 12 b and c, rightmost half of the blot). This suggested that
EP-39 favored the occurrence and/or the stability and persistence
of Gag trimers, versus higher order oligomers, as compared to
control samples. The cross-linking pattern of Gag in situ confirmed
our EM observation, and indicated that the Gag oligomerization
status and the mode of particle assembly were different in
untreated and EP-39-treated cells.
Discussion
Several methods have been proposed to quantify the HIV-1
assembly and budding process. Conventional techniques such as
CAp24 immunoassays used for clinical samples have the
inconvenience of not discriminating between soluble CAp24
protein released into the extracellular medium and CAp24 protein
incorporated into membrane-enveloped virus particles. On the
other hand, virus load assays based on genome copy number
determination explore the genome encapsidation process and not
specifically the capsid assembly, although RNA encapsidation and
virus assembly have been shown to be two linked phenomena [56–
59]. Several laboratories, including ours, have fused an enzyme to
the Gag precursor, e.g bacterial beta-galactosidase [31,60] or
firefly luciferase [22], to quantitate VLP in cell culture superna-
tants using enzymatic assays. Other methods have preconized the
fusion of Gag to enhanced green fluorescent protein from jellyfish
Aequorea (eGFP), to be able to monitor Gag assembly and budding
by flow cytometry, or by fluorescence microscopy in situ in cell
compartments [61,62].
Such methods present severe inconveniences and limitations. (i)
The addition of a protein tag to the Gag prolyprotein can only be
designed at the Gag C-terminus since the N-myristoyl group and
the N-terminal stretch of basic residues in the MA domain must be
kept intact for plasma membrane addressing and extracellular
budding. (ii) Fusion of Gag sequence to an enzyme can be
detrimental to the enzymatic activity, in particular for oligomeric
enzymes whose activities depend on a specific oligomeric status
incompatible with the Gag oligomers occurring during VLP
formation [63,64]. (iii) On the Gag side, the fusion of a protein
sequence to the C-terminus of Gag precursor can provoke a steric
hindrance which impairs Gag multimerization, assembly and/or
budding, or cellular release. This was the case for Gag-b-
galactosidase or Gag-protease fusion constructs : the resulting
VLP were irregular in shape and size, and hardly mimicked the
natural process of virus assembly and egress [28,31]. Likewise,
Gag-GFP fusion protein expressed alone has been found to follow
a cellular trafficking pathway different from that of WT Gag in the
context of natural HIV-1 cellular infection [61].
Vpr is one of the auxiliary proteins of HIV-1 which is involved
in the nuclear import of preintegration complex and cell cycle
arrest at the G2 phase of HIV-infected proliferating cells [65]. Vpr
is a low-molecular-weight protein (14 kDa) which is a structural
component of the infectious virions [46,51,52]. Vpr interacts with
Gag and is packaged at high copy numbers into immature
particles of HIV-1 [39], and this property has been advantageously
used to package various Vpr-fused proteins, including antiviral
factors [66–68]. The b-lactamase-Vpr construct was the first
fusion protein used to develop a sensitive Vpr-enzyme based assay
to monitor a specific step of the HIV-1 infection cycle, the HIV-1-
host cell fusion and entry [69]. In the present study, we took
advantage of the Vpr packaging property to construct a
recombinant baculovirus expressing a luciferase-Vpr fusion
protein (LucVpr), with the luciferase domain at the N-terminus
and the Vpr moiety at the C-terminus of the fusion, separated by a
flexible linker containing an oligo-histidine tag. When coexpressed
in Sf9 cells with the HIV-1 Gag precursor using recombinant
baculoviruses, the fusion protein LucVpr was coencapsidated with
Gag as efficiently as Vpr alone, with an average ratio of Gag to
Vpr molecule of 4.9 for LucVpr, versus 5.6 for Vpr.
Figure 9. Electron microscopy of EP-39-treated, Pr55Gag-expressing cells. Samples of Sf9 cells coinfected with AcMNPV-Pr55Gag and
AcMNPV-LucVpr at equal MOI, were treated at 24 h pi with 10 mg/ml of EP-39 inhibitor for 24 h, harvested at 48 h pi, and processed for observation
under the EM. Note the morula-like shape of electron-dense particles of ca. 100 nm in diameter, some of which in the process of egressing into the
extracellular milieu.
doi:10.1371/journal.pone.0027234.g009
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The production of HIV-1 VLP by recombinant baculovirus-
infected Sf9 cells has been shown to be high, with as much as 105
VLP per cell released in the extracellular medium at 48–72 h pi
[33]. It has been reported that one immature HIV-1 particle
contains approximately 5,000 copies of closely packed Pr55Gag
protein [70,71]. We estimated the VLP yields by scanning the
band of Pr55Gag in Coomassie blue-stained gels, using BSA as
protein standard. The Gag signal recovered in the VLP fractions
of the linear sucrose-D20 gradient (refer to Fig. 3) corresponded to
a total population of 261010 to 561010 VLP recovered from
26106 Sf9 cells. Based on our calculation of the Gag:LucVpr ratio
of about 5:1, the LucVpr content was 1,000 LucVpr molecules per
VLP. This implied that the luciferase signal emitted by the whole
VLP population corresponded to a total of 261013 to 561013
molecules of LucVpr. Since the molecular weight of the fusion
protein was 72 kDa (i.e. 661013 molecules corresponded to 7.2 mg
LucVpr protein), the total number of VLP-incorporated LucVpr
molecules (261013 to 561013) was equivalent to 2.4 to 6.0 mg
LucVpr protein in the whole VLP population.
It is generally estimated that purified recombinant luciferase
enzyme generates 106103 to 306103 RLU per mg luciferase
protein. The luciferase signal corresponding to 2.4 to 6.0 mg
LucVpr protein would theoretically range from 246103 to
1806103 RLU. The experimental values of luciferase activity
recovered from the sucrose-D20 gradient fractions varied between
56103 and 306103 RLU, depending on the experiments (refer to
Fig. 3 and Fig. 4 a). The relatively lower recovery in luciferase
activity, compared to the theoretical value calculated from the
packaging efficiency of LucVpr protein into VLP, could be due to:
(i) an incomplete dissociation of certain VLP and the inaccessibility
of some Gag-copackaged luciferase to its luciferin substrate; (ii) a
lower enzymatic activity of the LucVpr fusion compared to
nonfused, natural luciferase enzyme; (iii) the quenching of the
luciferase activity due to residual binding of the Vpr domain of
LucVpr to the p6 domain of the Pr55Gag precursor; (iv) all three
mechanisms.
Despite these minor inconveniences, the luciferase-based
quantification of VLP production by insect cells, as described
in the present study, represented a simple, rapid and low-cost
assay for the screening of potential HIV-1 assembly inhibitors in
a living cell system. We then applied this assay to the biological
characterization of a panel of betulinic acid derivatives which
only differed from the leader compound DSB (or PA-457) by
their substituant on carbon-28. The antiviral PA-457 has been
identified as an inhibitor of HIV-1 maturation in the nanomolar
range [10], and, in the micromolar range, as an inhibitor of VLP
assemby [12,54] and a stabilizer of virus particles in their
immature state [13]. We found that the glycine-conjugated DSB
Figure 10. Structural analysis of extracellular EP-39-induced morula-like particles. Sf9 cells infected with AcMNPV-Pr55Gag were
untreated (a) or treated (b, c) at 24 h pi with EP-39 (10 mg/ml) for 24 h. Cell culture medium was harvested at 48 h pi, VLP pelleted by
ultracentrifugation, and processed for EM analysis. Electron-dense 100-nm particles are viewed at low (b) and high (c) magnification, respectively.
Control, membrane-enveloped VLP released from untreated cells (a) are shown at the same magnification as in (c). (d), Hypothetical model of an EP-
39-induced nanoparticle of ca. 20 nm in diameter, composed of 12 to 16 copies of Pr55Gag assembled with a dodecahedral or octahedral symmetry.
doi:10.1371/journal.pone.0027234.g010
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(ST-327) and e-N-amidified, Boc-lysine-conjugated DSB (EP-47)
exerted a similar type of viral assembly inhibition as PA-457,
although with a 2-fold higher efficacy for EP-47, compared to
PA-457 and ST-327. However, the high cytotoxicity of EP-48,
the beta-alanine-conjugated DSB, and of EP-62, the lysine-
conjugated DSB with free lysine e-NH2 group, made these
compounds useless for further antiviral applications. Our EM
observations showed that ST-327 and EP-47, as well as
previously shown for PA-457 [12], blocked the virus assembly
machinery in two cellular compartments, (i) at the plasma
membrane when using budding-competent, N-myristoylated
Gag precursor, and (ii) within the cytoplasm, when using
budding-defective, non-N-myristoylated Gag precursor. This
blockage occurred in a dose-dependent manner, with no
detectable qualitative alterations of the VLP or core-like
morphology [12].
The ethylene diamine-conjugated DSB (EP-39) was also found
to inhibit the assembly of HIV-1 VLP, but in a manner which
differed from that of the three other compounds PA-457, ST-327
and EP-47. EP-39 altered the viral assembly pathway in two
manners. (i) It provoked the cytoplasmic assembly of an aberrant
type of Gag particles never observed so far, morula-like particles of
ca. 100-nm in diameter different in size and shape from the core-
like particles formed of non-N-myristoylated Gag polyprotein [25-
27,32,33,53]. (ii) EP-39 did not inhibit the addressing to the cell
surface of these morulae, but blocked their membrane wrapping,
resulting in the release into the extracellular medium of uncoated
Gag morula-like particles, recovered in the pelletable fraction in
Figure 11. Immunoelectron microscopy (IEM) of EP-39-treated, Pr55Gag-expressing cells. Samples of AcMNPV-Gag-infected Sf9 cells
were treated at 24 h pi with EP39 (10 mg/ml) for 24 h, harvested at 48 h pi, fixed and processed for IEM analysis. Ultrathin sections were incubated
with rabbit anti-Gag antibody followed by 10-nm colloidal gold-tagged goat anti-rabbit IgG antibody. Panel (a) shows a festooned aspect of the cell
surface, suggesting an abortive budding of particles. Panels (b) and (c) show immunogold-labeling associated with cytoplasmic 20-nm nanoparticles
and with aberrant particles protruding from the plasma membrane. Note that the fainter staining of the specimens, compared to conventional
electron microscopy (refer to Fig. 8-10), was destined to enhance the contrast between the colloidal gold grains and the background.
doi:10.1371/journal.pone.0027234.g011
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association with LucVpr. This explained the occurrence of a peak
of luciferase activity co-sedimenting with Gag, and the apparent
residual VLP production observed in the presence of EP-39, using
our luciderase assays. Bona fide membrane-enveloped VLP and
nonenveloped morula-like assemblies could easily be discriminated
by their densities in isopycnic ultracentrifugation.
Ultrastructural analysis of the morula-like particles showed that
they were composed of nanoparticular subunits of ca. 20-nm in
diameter. The volume of these 20 nm-nanoparticles was theoret-
ically sufficient to harbor 12 to 16 copies of Pr55Gag, arranged as
a dodecahedron, decahedron, octahedron, or another type of solid
of Platon. Biological nanoparticles composed of viral capsid
components or subdomains thereof have already been described
and characterized. E.g., twelve penton capsomeres of human
adenovirus serotype 3 can form a symmetrical structure called
penton dodecahedrons [72–74]. Likewise, dodecamers of P
domain dimers of the protrusion (P) domain of the Norovirus
capsid protein could assemble into octahedral structures of 20 nm
in diameter, called Norovirus P nanoparticles. Each P nanoparticle
of 24 subunits accommodated for a total protein mass of 840 kDa
Figure 12. BS3 cross-linking of intracellular Pr55Gag in untreated and EP-39-treated cells. Luminograms of SDS-PAGE and Western blot
analysis of recombinant Gag polyproteins cross-linked in situ in untreated and EP-39 treated (10 mg/ml) Sf9 cells at 48 h pi. The spacer gel (delineated
with dotted lines) was kept intact during the transfer of proteins to the membrane, as it potentially contained high order oligomers of Gag or/and
aggregates of high molecular mass, too large to enter the resolving gel. Panel (a) corresponds to underexposed control lanes 0 (without BS3 cross-
linking) from the blot shown in panel (b). Panel (c) is an enlargement and overexposure of the top of panel (b).
doi:10.1371/journal.pone.0027234.g012
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[75]. Based on this calculation, we estimated the Pr55Gag content
of one nanoparticle of 19.4-nm in diameter to range from 12
(12655= 660 kDa) to 16 copies of Pr55Gag (16655= 880 kDa),
arranged as a dodecahedron, decahedron, octahedron, or any
other solid of Platon (Fig. 10 d).
It was impossible to determine the exact number of nanopar-
ticles per morula-like particles of Gag assembled in the presence of
EP-39. However, there was no indication of an internal cavity
within the morula, and a maximum of 20 individual beads could
be simultaneously discerned on section planes of 100 nm-morulae,
implying that the 60 nm-thick ultrathin section had passed
through their equatorial plane. If we consider that one morula
could be inscribed in a cube of 100 nm in edge, and since each
edge would accomodate 5 beads each, each morula would
theoretically contain 125 beads or nanoparticles of 20-nm
(56565= 125), with a total number of Pr55Gag copies ranging
between 1,500 (125612) and 2,000 (125616). Alternatively, if the
morula adopted the structure of an icosahedron of roughly
100 nm in diameter and constituted of 180 nanoparticles, the total
number of Pr55Gag copies would range between 2,160 (180612)
and 2,880 (180616).
Of note, when administered to mammalian cells, EP39 also
provoked aberrant assembly of HIV-1 particles: virions lacked
conical cores, and instead contained spherical, acentric cores, and
an additional electrondense layer beneath the viral envelope.
However, no 100-nm morula-like or 20-nm nanoparticles were
detected [55]. The structural differences with our recombinant
Pr55Gag-expressing cells confirmed that viral proteins other than
the Gag precursor, as well as the viral genome, contributed to
virion formation [15,76], and could partially compensate for the
EP-39-induced Gag defect.
HIV-1 GagA364V is the prototype of a series of PA-457-
resistant Gag mutants showing a normal or subnormal pattern of
PR-mediated Gag processing in the presence of inhibitory doses of
PA-457 [6,11,77,78]. Based on the resistance to PA-457 conferred
by A364V and other mutants of similar phenotype, the alanine
residue at position 364 in the Pr55Gag sequence (position 1 of the
SP1 domain) and its flanking regions in the CA and SP1 domains
have been assumed to represent the main target of PA-457
[5,6,10,11,77,78]. We therefore substituted the alanine residue for
valine at codon-364 in the gag sequence of the baculoviral clone
AcMNPV-Pr55Gag, in order to analyze the sensitivity of the
GagA364V mutant to EP-39, in terms of assembly and budding of
VLP from GagA364V-expressing cells. Unfortunately, we found
that the GagA364V mutant was unstable in Sf9 cells, due to a
premature cleavage near the CA-SP1 junction by cellular
proteases, resulting in a major 41 kDa product (data not shown).
This unstability prevented any study on the possible influence of
the Ala-to-Val mutation at position 1 of the SP1 domain on the
EP-39-mediated inhibition of VLP assembly.
Our preliminary NMR analysis indicated that the amino acid
residues engaged in the interaction of Gag with EP-39 mapped to
the SP1 domain (to be published). The EP-39 assembly inhibitor
therefore provided some clues to the understanding of Gag
interaction and oligomerization, and the possible mode(s) of Gag
assembly at the polyprotein level, at steps preceding the formation
of Gag immature particles [79]. Two hypotheses could be
formulated to explain the pattern of Gag assembly in the presence
of EP-39. (i) The 20 nm-nanoparticles might represent transient
and/or labile Gag assembly intermediates which were blocked in
their particular oligomeric status by EP-39. (ii) In a previous work,
we showed that a Gag-derived polypeptide containing the SP1
domain could both dimerize and trimerize : contacts occurring at
the hydrophobic surface of the region of CA-SP1 junction dimers
would generate dimers, whereas trimers would result from contacts
made at its hydrophilic surface [80]. EP-39 might block one or the
other type of SP1-mediated inter-Gag contacts and favor one type
of oligomerization process, or stabilize one particular form of Gag
oligomers, e.g. the trimers. Isolation of 20 nm-nanoparticles
induced by EP-39 is now in progress to determine their
ultrastructure and type of symmetry using cryoelectron microsco-
py and tomography.
In conclusion, our study confirmed the necessity to develop
sensitive and reliable assays to investigate HIV-1 virus assembly
which were not simply based on CAp24 immunoassays. This
would allow the quantitave evaluation of the efficacy of antivirals
which target the final steps of HIV-1 productive cycle, assembly
and budding. Our luciferase-Vpr packaging-based assay for the
quantification of HIV-1 VLP production in insect cells led us to
characterize a novel antiviral activity associated with EP-39, a
derivative of betulinic acid corresponding to ethylene diamine-
substituted PA-457. Our results demonstrated the importance of
the side chains on carbon-28 of betulinic acid in the antiviral effect
of DSB derivatives. Previous studies have shown that several
carbon-28 substituants of betulinic acid have an antiviral effect at
the post-entry step of HIV-1 infection, probably by interference
with the viral-cell membrane fusion [49,50,81,82]. Our data
confirmed this membrane-targeting function, and suggested that
betulinic acid would act as an anti-HIV prodrug with a multipolar
activity, depending on its substituants. (i) Substituants on carbon-
28, e.g. RPR-103611 [49,50,81,82], would mainly interfere with
membrane fusion, whereas (ii) substituants on carbon-3 (e.g. PA-
457), and double substituants on both carbon-3 and carbon-28
(e.g. ST-327) would negatively interfere with virus maturation at
low doses [5,8,10,11,55] and on immature particle assembly [12]
and stability [13] at higher doses. (iii) The double substituant EP-
39 showed a peculiar type of inhibitory effect, in that it altered not
only the maturation and structure of the virus particles [55] but
also the Gag precursor assembly, the membrane wrapping and
budding process of immature Gag particles (this study). Our
observation on the critical role of the side chain at position 28 in
the anti-HIV-1 activity of betulinic acid derivatives had important
implications in the design of future antivirals belonging to the
betulinic acid family.
Materials and Methods
Chemical synthesis of betulinic acid (BA) derivatives
The leader compound 3-O-(3’,3’-dimethylsuccinyl)-betulinic
acid (DSB or PA-457; C36H56O6; MW=584.8; DSB-28COOH)
was synthesized from commercially available betulinic acid (BA;
MW=456.7; MP Biochemicals, France) as originally described
[7], with some minor modifications reported in our previous study
[12]. Glycine-conjugated DSB (DSB-28CO-Gly; ST-327;
MW=641.8), beta-alanine-conjugated DSB (DSB-28CO-bAla;
EP-48; MW=655.4), ethylene diamine-conjugated (DSB-28CO-
EDA; EP-39; MW=626.5), e-N-tert-butoxycarbonyl-lysine-conju-
gated DSB (DSB-28CO-Lys-e-NH-Boc; EP-47; MW=812.5), and
lysine-conjugated DSB with with free lysine e-NH2 group
(DSB-28CO-Lys; EP-62; MW=712.5) were synthesized according
to a published procedure [83], with some modifications. Detailed
synthesis procedures will be published elsewhere [55], and vailable
upon request. A schematic representation of these compounds is
shown in Fig. 5.
Cells and recombinant baculoviruses
(i) Insect cells. Spodoptera frugiperda Sf9 cells were maintained as
monolayers, and infected with recombinant baculoviruses at a
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multiplicity of infection (MOI) ranging from 5 to 10 PFU/cell, as
previously described [25,26,30,32,33]. (ii) Gag clones. The
HIV-1 gag gene, as well as the luciferase-vpr fusion gene, used in the
present study were inserted into the genome of Autographa californica
MultiCapsid NucleoPolyhedrosis Virus (AcMNPV) under the
control of a chimeric AcMNPV-GmMNPV polyhedrin promoter,
and the phenotypes of recombinant Gag proteins described in
detail in previous studies [25,26,32,33]. AcMNPV-Pr55Gag
expressed the full-length wild type (WT) Gag polyprotein
(Pr55Gag). The recombinant expressing the N-myristoylated
version of the deletion mutant lacking the p6 carboxy-terminal
domain, referred to as AcMNPV-GagDp6(myr+) in previous
studies [12,28,53] was simply referred to as AcMNPV-GagDp6 for
reason of acronym simplification. In AcMNPV-GagA364V
mutant, the first residue of the SP1 domain, alanine, was mutated
into valine, using the conventional PCR overlapping method, and
the GagA364V mutation verified by DNA sequencing. (iii) Vpr.
The baculovirus clone expressing the oligohistidine-tagged Vpr
protein (AcMNPV-Vpr) was obtained from Nathaniel Landau via
Eric Cohen [84]. (iv) Luciferase-Vpr fusion construct
(LucVpr). The plasmid carrying the vpr gene (LAI isolate) was
obtained from Serge Benichou [47]. The firefly (Photinus pyralis)
luciferase gene sequence was isolated by PCR from the pGL2
plasmid (control plasmid Cat # E1611; Promega). After deletion
of its stop codon, a sequence coding for a 6-histidine tag and a
GSGS linker was inserted at its 3’-end, and fused to the 5’-end of
the vpr gene. The detail of this construct will be communicated
upon request. The final fusion construct luc(his)6-vpr was inserted
into AcMNPV to generate the AcMNPV-LucVpr recombinant.
Of note, the reverse gene fusion vpr-3’-luc(his)6 was also
constructed, but the VprLuc fusion protein was found to be
incapable of copackaging with Pr55Gag into VLP.
Isolation of extracellular virus-like particles (VLP)
Sf9 cell culture supernatants were clarified by low-speed
centrifugation, then VLP recovered using a two-step procedure
comprising a sucrose-step gradient centrifugation [76], followed by
an ultracentrifugation in linear D2O-sucrose gradient [12,53]. (i)
In the first step, VLP contained in the cell culture medium were
pelleted through a sucrose cushion (20%, w:v, in TNE buffer;
TNE: 100 mM NaCl, 10 mM Tris-HCl pH 7.4, 1 mM
Na2EDTA) at 30 krpm for 1 h at 15uC in a Kontron TST55.5
rotor [12]. Pelleted VLP of step (i) were then gently resuspended in
PBS (0.20–0.25 ml), and (ii) further analyzed by isopycnic
ultracentrifugation in sucrose-D2O gradients [12,53]. Linear
gradients (10-ml total volume, 30–50%, w:v) were centrifuged
for 18 h at 28 krpm in a Beckman SW41 rotor. The 50% sucrose
solution was made in D2O buffered to pH 7.2 with NaOH, and
the 30% sucrose solution was made in 10 mM Tris-HCl, pH 7.2,
150 mM NaCl, 5.7 mM Na2EDTA. Aliquots of 0.5 ml were
collected from the top, and fractions analyzed for protein content
by SDS-PAGE and immunoblotting, and by luciferase assay as
described below.
Gag assembly inhibition assays
Aliquots of Sf9 cells (106) were infected with two recombinant
baculoviruses at equal multiplicity of infection (MOI of 10 PFU/
cell, each). One expressed the HIV-1 Gag precursor (AcMNPV-
Pr55Gag or control, p6-deleted AcMNPV-GagDp6), the other the
control Vpr protein (AcMNPV-Vpr) or the LucVpr fusion
(AcMNPV-LucVpr). At 24 h postinfection (pi), increasing quan-
tities of PA-457, ST-327, EP-39 or EP-47 in DMSO were added to
the infected cell cultures. To avoid any interference with a possible
effect of DMSO, DMSO was kept constant in volume in the
different samples. In standard experiments, stock solutions of PA-
457, ST-327, EP-39 or EP-47 (10 mg/ml in DMSO) were diluted
with DMSO to obtain a range of inhibitor concentrations from 0.5
to 20 mg per 2 ml-aliquot of DMSO, and each 2 ml-aliquot was
added per 1 ml-volume of culture medium overlaying cell
monolayers. Cells were harvested at 48 h pi, and extracellular
VLP released in the culture medium were quantitated using
luciferase assay. Membrane-enveloped VLP were pelleted and
resuspended in lysis KDT buffer (KDT: 0.1 M potassium
phosphate buffer, pH 7.8, 1 mM DTT, containing 0.2% Triton
X100) for 30 min at 37uC with vortexing every 10 min. Luciferase
activity associated with VLP was measured as previously described
[85], using a Lumat LB-9501 luminometer (Berthold Technolo-
gies, Bad Wildbad, Germany). Of note, final concentrations of
Triton X100 higher than 0.2% in samples were found to have a
detrimental effect on the luciferase enzymatic activity. To
compensate for eventual negative effects of drugs on LucVpr
expression, the luciferase activity was measured in the corre-
sponding cell lysates, obtained after lysis of the pelleted cells with
KDT buffer. The results were expressed as relative light units
(RLU) per mg protein. The values of the ratio of VLP-associated to
intracellular luciferase activity were plotted versus the inhibitor
concentration. The 50% inhibitory concentration (IC50) was
defined as the compound concentration required to reduce this
ratio by 50%, compared to the ratio obtained with untreated cells
which was attributed the 100% value.
Cytotoxicity assays
The cellular toxicity of the different compounds was evaluated
using the MTT assays [86]. The 50% cytotoxic concentration
(CC50) was defined as the concentration of the compound which
reduced the cell viability by 50%, compared to that of untreated
controls. The selectivity index (SI) was defined as the CC50 to IC50
ratio.
Gel electrophoresis and quantitative assays of proteins
Polyacrylamide gel electrophoresis of SDS-denatured protein
samples (SDS-PAGE), and immunoblotting analysis have been
described in detail in previous studies [12,25,26,53,87]. Briefly,
proteins were electrophoresed in SDS-denaturing, 10%- or 15%-
polyacrylamide gel, along with prestained protein markers
(PageRulerTM prestained protein ladder; Fermentas Inc., Han-
over, MD, or Dual ColorTM Standards, BioRad), and electrically
transferred to nitrocellulose membrane (HybondTM-C-extra; GE
Healthcare Bio-Sciences). Blots were blocked in 5% skimmed milk
in Tris-buffered saline (TBS) containing 0.05% Tween-20 (TBS-
T), rinsed in TBS-T, then successively incubated with primary
rabbit or mouse anti-Gag antibodies, and relevant anti-IgG
secondary antibodies, at working dilutions ranging from 1:1,000
to 1:10,000. Anti-HIV-1 Gag polyclonal antibody (laboratory-
made; [53]) was raised in rabbit by injection of bacterially-
expressed, GST-fused and affinity-purified C-truncated Gag
protein consisting of full-length MA domain and the first
seventy-eight residues of the CA domain (Pst I site; gagLai
sequence). Mouse monoclonal antibody (mAb) anti-CAp24
(Epiclone #5001) and mAb anti-MAp17 (Epiclone #5003) were
obtained from Cylex Inc. (Columbia, MD). Mouse monoclonal
anti-oligo-histidine antibody was purchased from Quiagen S.A.
(Courtaboeuf, France). Phosphatase-labeled anti-rabbit, or anti-
mouse IgG conjugates were purchased from Sigma (St Louis,
MO). For immunological quantification of VLP or VLP protein
content, membrane-transferred protein were reacted with their
specific primary antibody, then with 125I-labeled protein A (MP
Biomedicals France, 67402 Illkirch; specific activity 30 mCi/mg)
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used at 20–30 mCi per 100 cm2 membrane, and exposed to
radiographic films (Kodak BioMax HE filmTM, Sigma-Aldrich,
38297-St Quentin-Fallavier). Autoradiograms were scanned and
quantitated by densitometric analysis, using the VersaDoc image
analyzer and the Quantity One program (BioRad), or protein
bands were excised from blots and radioactivity measured in a
scintillation counter (Beckman LS-6500), as previously described
[12,53]. Alternatively, quantification of proteins in VLP was also
performed using radiolabeling of proteins. Baculovirus-infected
cells samples were labeled with 35S-amino acids (ICN Pharma-
ceuticals France, 91898-Orsay ; Tran35S-LABELTM; specific
activity .1,000 Ci/mmol), added at 15 mCi/ml in methionine-
free medium for 30 h at 18 h pi in the absence or presence of
inhibitor in DMSO. VLP were recovered from the cell culture
medium as described above, and radioactive proteins analysed by
SDS-PAGE and autoradiography of dried gels.
Electron microscopy and immuno-electron microscopy
Baculovirus-infected Sf9 cells were harvested at 48 h pi,
pelleted, fixed with 2.5% glutaraldehyde in 0.1 M phosphate
buffer, pH 7.5, post-fixed with osmium tetroxide (2% in H2O) and
treated with 0.5% tannic acid solution in H2O. The specimens
were dehydrated and embedded in Epon (Epon-812; Fulham,
Latham, NY). Ultrathin sections were stained with 2.6% alkaline
lead citrate and 0.5% uranyl acetate in 50% ethanol, and post-
stained with 0.5% uranyl acetate solution in H2O [12,28,53].
Grids were examined under a Jeol JEM-1400 electron microscope,
equiped with an ORIUSTM digitalized camera (Gatan France,
78113-Grandchamp). For statistical EM analyses, a minimum of
30 grid squares containing 10 to 20 cell sections each were
examined for counting VLP budding at the cell surface, or
budding in intracellular vesicular compartment.
For immuno-electron microscopy, specimens were fixed with
4% paraformaldehyde in 0.1 M phosphate buffer pH 7.3 for 4 h,
post-fixed with 1% glutaradehyde in 0.1 M phosphate buffer
pH 7.3 for 4 h, then rinsed overnight in 0.1 M phosphate buffer
pH 7.3. After dehydration, specimens were included in LR White
hydrophilic resin (Electron Microscopy Sciences, Hatfield, PA;
EMS Catalog# 14380), and ultrathin sections deposited on nickel-
coated grids. Grids were incubated with anti-Gag rabbit antibody
(laboratory-made; [53]) at a dilution of 1:50 in TBS for 1 h at
room temperature (RT). After rinsing with TBS, the grids were
post-incubated with 10-nm colloidal gold-tagged goat anti-rabbit
IgG antibody (British Biocell International Ltd, Cardiff, UK;
diluted to 1:50 in TBS) for 30 min at RT. After rinsing with TBS,
the specimens were post-stained with 1% uranyl acetate in H20 for
1 min at RT, rinsed again with TBS, and examined under the
electron microscope.
Chemical cross-linking of intracellular Pr55Gag
Aliquots of recombinant baculovirus-infected Sf9 cells (56105
cells) untreated or treated with EP-39 at 10 mg/ml for 24 h at 24 h
pi were centrifuged at low speed, resuspended in 200 ml of PBS
containing the cross-linker bis(sulfosuccinimidyl)suberate (BS3;
Pierce Biotechnology, Rockford, IL) at increasing molarities,
ranging from 0 to 50 mM [88], and incubated in this buffer for
30 min at room temperature (RT). Cell samples were then
centrifuged, resuspended and lysed in 200 ml 0.015 M NaCl,
0.5 mM phosphate buffer pH 7.3 containing BS3 at the same
molarites as in the original mixtures, and further incubated for
30 min at RT. Cell lysates were mixed with 30 ml 6 times
concentrated (6x) SDS-sample buffer without b-mercaptoethanol,
heated to 100uC for 1 min, and Gag proteins analyzed by SDS-
PAGE and immunoblotting. Western blots (Amersham Hy-
bondTM-ECL; GE-Healthcare) were incubated with polyclonal
anti-Gag rabbit serum (laboratory-made; [53]) diluted to 1:3,000
for 3 h at RT, followed by peroxidase-labeled anti-rabbit IgG
(Sigma; dilution 1:10,000) for 1 h at RT. Blots were then reacted
with SuperSignalH West Pico chemiluminescence substrate (Pierce
Biotechnology), and luminograms were visualized using the Fusion
X7 imaging system with the Bio1D software (Vuilbert-Lourmat,
Marne-la-Valle´e, France).
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